Click here to get full coverage on MaxCyte (NASDAQ: MXCT) investors reelect board and ratify auditor - Stock Titan

MaxCyte (NASDAQ: MXCT) investors reelect board and ratify auditor  Stock Titan

MaxCyte (NASDAQ: MXCT) investors reelect board and ratify auditor - Stock Titan

Click here to get full coverage on MaxCyte Disclosed Failure to Satisfy a Continued Listing Rule or Standard - TradingView

MaxCyte Disclosed Failure to Satisfy a Continued Listing Rule or Standard  TradingView

MaxCyte Disclosed Failure to Satisfy a Continued Listing Rule or Standard - TradingView

Click here to get full coverage on MaxCyte (MXCT) Launches ExPERT DTx Platform to Accelerate High-Throughput Drug Discovery - Yahoo Finance

MaxCyte (MXCT) Launches ExPERT DTx Platform to Accelerate High-Throughput Drug Discovery  Yahoo Finance

MaxCyte (MXCT) Launches ExPERT DTx Platform to Accelerate High-Throughput Drug Discovery - Yahoo Finance

Click here to get full coverage on MaxCyte (NASDAQ: MXCT) restores Nasdaq minimum bid-price compliance after warning - Stock Titan

MaxCyte (NASDAQ: MXCT) restores Nasdaq minimum bid-price compliance after warning  Stock Titan

MaxCyte (NASDAQ: MXCT) restores Nasdaq minimum bid-price compliance after warning - Stock Titan

Click here to get full coverage on MaxCyte Inc. (MXCT) Stock Falls on Q4 2025 Earnings - Quiver Quantitative

MaxCyte Inc. (MXCT) Stock Falls on Q4 2025 Earnings  Quiver Quantitative

MaxCyte Inc. (MXCT) Stock Falls on Q4 2025 Earnings - Quiver Quantitative

Click here to get full coverage on MaxCyte Inc (MXCT) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey

MaxCyte Inc (MXCT) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution  TradingKey

MaxCyte Inc (MXCT) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey

Click here to get full coverage on MaxCyte (NASDAQ:MXCT) Q1 2026 Results Beat Estimates, Stock Rises on Buyback - ChartMill

MaxCyte (NASDAQ:MXCT) Q1 2026 Results Beat Estimates, Stock Rises on Buyback  ChartMill

MaxCyte (NASDAQ:MXCT) Q1 2026 Results Beat Estimates, Stock Rises on Buyback - ChartMill

Click here to get full coverage on MaxCyte (MXCT) EPS Loss Narrows In Q1 2026 Challenging Bearish Profitability Narratives - simplywall.st

MaxCyte (MXCT) EPS Loss Narrows In Q1 2026 Challenging Bearish Profitability Narratives  simplywall.st

MaxCyte (MXCT) EPS Loss Narrows In Q1 2026 Challenging Bearish Profitability Narratives - simplywall.st

Click here to get full coverage on MaxCyte, Inc. (MXCT) Announces Results of Shareholder Vote and Audit Firm Ratification – June 17, 2026 - Minichart

MaxCyte, Inc. (MXCT) Announces Results of Shareholder Vote and Audit Firm Ratification – June 17, 2026  Minichart

MaxCyte, Inc. (MXCT) Announces Results of Shareholder Vote and Audit Firm Ratification – June 17, 2026 - Minichart

Click here to get full coverage on MaxCyte, Inc. (MXCT) Reports Q4 Loss, Misses Revenue Estimates - Yahoo Finance

MaxCyte, Inc. (MXCT) Reports Q4 Loss, Misses Revenue Estimates  Yahoo Finance

MaxCyte, Inc. (MXCT) Reports Q4 Loss, Misses Revenue Estimates - Yahoo Finance

Click here to get full coverage on MaxCyte Inc (MXCT) Institutional Confidence - TradingKey

MaxCyte Inc (MXCT) Institutional Confidence  TradingKey

MaxCyte Inc (MXCT) Institutional Confidence - TradingKey

Click here to get full coverage on MaxCyte Inc (MXCT) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey

MaxCyte Inc (MXCT) Earnings Forecast: Future EPS & Revenue Growth Estimates  TradingKey

MaxCyte Inc (MXCT) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey

Click here to get full coverage on MaxCyte (NASDAQ: MXCT) Q1 2026 revenue $9.7M as board approves $10M buyback - Stock Titan

MaxCyte (NASDAQ: MXCT) Q1 2026 revenue $9.7M as board approves $10M buyback  Stock Titan

MaxCyte (NASDAQ: MXCT) Q1 2026 revenue $9.7M as board approves $10M buyback - Stock Titan

Click here to get full coverage on MaxCyte Inc (MXCT) Financial Health: Profitability & Balance Sheet Analysis - TradingKey

MaxCyte Inc (MXCT) Financial Health: Profitability & Balance Sheet Analysis  TradingKey

MaxCyte Inc (MXCT) Financial Health: Profitability & Balance Sheet Analysis - TradingKey

Click here to get full coverage on MaxCyte sees $30M-$32M in 2026 sales after 2025 revenue fell 15% - Stock Titan

MaxCyte sees $30M-$32M in 2026 sales after 2025 revenue fell 15%  Stock Titan

MaxCyte sees $30M-$32M in 2026 sales after 2025 revenue fell 15% - Stock Titan

Click here to get full coverage on MaxCyte Inc (MXCT) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey

MaxCyte Inc (MXCT) Technical Analysis: Support, Resistance, Indicators & Moving Averages  TradingKey

MaxCyte Inc (MXCT) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey

Click here to get full coverage on New MaxCyte lab device runs 96 cell samples in a three-minute cycle - Stock Titan

New MaxCyte lab device runs 96 cell samples in a three-minute cycle  Stock Titan

New MaxCyte lab device runs 96 cell samples in a three-minute cycle - Stock Titan

Click here to get full coverage on MaxCyte Inc (MXCT) Valuation: PE, PB & Fair Value Analysis - TradingKey

MaxCyte Inc (MXCT) Valuation: PE, PB & Fair Value Analysis  TradingKey

MaxCyte Inc (MXCT) Valuation: PE, PB & Fair Value Analysis - TradingKey

Click here to get full coverage on MaxCyte Inc (MXCT) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey

MaxCyte Inc (MXCT) Shareholder Structure: Major Shareholders & Institutional Holdings  TradingKey

MaxCyte Inc (MXCT) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey

Click here to get full coverage on MaxCyte Inc (MXCT) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey

MaxCyte Inc (MXCT) Risk Assessment: Volatility, Financial Risk & Investment Risk  TradingKey

MaxCyte Inc (MXCT) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey

Click here to get full coverage on MaxCyte shareholders elect directors and approve auditor at annual meeting By Investing.com - Investing.com Nigeria

MaxCyte shareholders elect directors and approve auditor at annual meeting By Investing.com  Investing.com Nigeria

MaxCyte shareholders elect directors and approve auditor at annual meeting By Investing.com - Investing.com Nigeria

Click here to get full coverage on Craig-Hallum Maintains MaxCyte(MXCT.US) With Buy Rating - 富途牛牛

Craig-Hallum Maintains MaxCyte(MXCT.US) With Buy Rating  富途牛牛

Craig-Hallum Maintains MaxCyte(MXCT.US) With Buy Rating - 富途牛牛

Click here to get full coverage on MaxCyte, Inc. to Release Fourth Quarter and Full Year 2025 Financial Results on March 24, 2026 - Quiver Quantitative

MaxCyte, Inc. to Release Fourth Quarter and Full Year 2025 Financial Results on March 24, 2026  Quiver Quantitative

MaxCyte, Inc. to Release Fourth Quarter and Full Year 2025 Financial Results on March 24, 2026 - Quiver Quantitative

Click here to get full coverage on MaxCyte schedules March 24 call on 2025 results for 4:30 p.m. ET - Stock Titan

MaxCyte schedules March 24 call on 2025 results for 4:30 p.m. ET  Stock Titan

MaxCyte schedules March 24 call on 2025 results for 4:30 p.m. ET - Stock Titan

Click here to get full coverage on MaxCyte Stock: A Guide to MXCT Market Performance - Bitget

MaxCyte Stock: A Guide to MXCT Market Performance  Bitget

MaxCyte Stock: A Guide to MXCT Market Performance - Bitget

Click here to get full coverage on MaxCyte, Inc. (MXCT) stock price prediction 2026–2030 - Bitget

MaxCyte, Inc. (MXCT) stock price prediction 2026–2030  Bitget

MaxCyte, Inc. (MXCT) stock price prediction 2026–2030 - Bitget

Click here to get full coverage on MXCT | MaxCyte, Inc. Common Stock Institutional Ownership - Quiver Quantitative

MXCT | MaxCyte, Inc. Common Stock Institutional Ownership  Quiver Quantitative

MXCT | MaxCyte, Inc. Common Stock Institutional Ownership - Quiver Quantitative

Click here to get full coverage on MAXCYTE, INC. 1Q 2026: Revenue $9.65M, EPS ($0.04) — 10-Q Summary - TradingView

MAXCYTE, INC. 1Q 2026: Revenue $9.65M, EPS ($0.04) — 10-Q Summary  TradingView

MAXCYTE, INC. 1Q 2026: Revenue $9.65M, EPS ($0.04) — 10-Q Summary - TradingView

Click here to get full coverage on symbol__ Stock Quote Price and Forecast - CNN

symbol__ Stock Quote Price and Forecast  CNN

symbol__ Stock Quote Price and Forecast - CNN

Click here to get full coverage on MaxCyte Stock - chart levels and volatility on a quiet news day - AD HOC NEWS

MaxCyte Stock - chart levels and volatility on a quiet news day  AD HOC NEWS

MaxCyte Stock - chart levels and volatility on a quiet news day - AD HOC NEWS

Click here to get full coverage on MaxCyte 2025 10‑K: Revenue $33.0M, EPS $(0.42) - TradingView

MaxCyte 2025 10‑K: Revenue $33.0M, EPS $(0.42)  TradingView

MaxCyte 2025 10‑K: Revenue $33.0M, EPS $(0.42) - TradingView

Click here to get full coverage on Glancy Prongay & Murray LLP Announces Investigation of MaxCyte, Inc. (MXCT) - Business Wire

Glancy Prongay & Murray LLP Announces Investigation of MaxCyte, Inc. (MXCT)  Business Wire

Glancy Prongay & Murray LLP Announces Investigation of MaxCyte, Inc. (MXCT) - Business Wire

Click here to get full coverage on MaxCyte Inc stock (US57777K1060): cell-therapy enabler after recent earnings update - AD HOC NEWS

MaxCyte Inc stock (US57777K1060): cell-therapy enabler after recent earnings update  AD HOC NEWS

MaxCyte Inc stock (US57777K1060): cell-therapy enabler after recent earnings update - AD HOC NEWS

Click here to get full coverage on MXCT Stock Price and Chart — NASDAQ:MXCT - TradingView

MXCT Stock Price and Chart — NASDAQ:MXCT  TradingView

MXCT Stock Price and Chart — NASDAQ:MXCT - TradingView

Click here to get full coverage on What is the current Price Target and Forecast for MaxCyte (MXCT) - Zacks Investment Research

What is the current Price Target and Forecast for MaxCyte (MXCT)  Zacks Investment Research

What is the current Price Target and Forecast for MaxCyte (MXCT) - Zacks Investment Research

Click here to get full coverage on MaxCyte Completes Operational Review, Adjusts Workforce, and Raises 2024 Revenue Guidance - Quiver Quantitative

MaxCyte Completes Operational Review, Adjusts Workforce, and Raises 2024 Revenue Guidance  Quiver Quantitative

MaxCyte Completes Operational Review, Adjusts Workforce, and Raises 2024 Revenue Guidance - Quiver Quantitative

Click here to get full coverage on MXCT Forecast — Price Prediction for 2026. Should I Buy MXCT? - Intellectia AI

MXCT Forecast — Price Prediction for 2026. Should I Buy MXCT?  Intellectia AI

MXCT Forecast — Price Prediction for 2026. Should I Buy MXCT? - Intellectia AI

Click here to get full coverage on Photo Galleries - Oklahoma State University Athletics

Photo Galleries  Oklahoma State University Athletics

Photo Galleries - Oklahoma State University Athletics

Click here to get full coverage on MXCT Forecast — Price Target — Prediction for 2027 - TradingView

MXCT Forecast — Price Target — Prediction for 2027  TradingView

MXCT Forecast — Price Target — Prediction for 2027 - TradingView

Click here to get full coverage on MaxCyte, Inc. Acquires SeQure Dx to Enhance Cell and Gene Therapy Solutions - Quiver Quantitative

MaxCyte, Inc. Acquires SeQure Dx to Enhance Cell and Gene Therapy Solutions  Quiver Quantitative

MaxCyte, Inc. Acquires SeQure Dx to Enhance Cell and Gene Therapy Solutions - Quiver Quantitative

Click here to get full coverage on Should I buy MaxCyte (MXCT) - Zacks Investment Research

Should I buy MaxCyte (MXCT)  Zacks Investment Research

Should I buy MaxCyte (MXCT) - Zacks Investment Research

Click here to get full coverage on CRISPR Therapeutics to use MaxCyte’s technology in its search for cancer gene therapies - Proactive financial news

CRISPR Therapeutics to use MaxCyte’s technology in its search for cancer gene therapies  Proactive financial news

CRISPR Therapeutics to use MaxCyte’s technology in its search for cancer gene therapies - Proactive financial news

Click here to get full coverage on MaxCyte Regains Nasdaq Compliance After Bid Price Recovery - TipRanks

MaxCyte Regains Nasdaq Compliance After Bid Price Recovery  TipRanks

MaxCyte Regains Nasdaq Compliance After Bid Price Recovery - TipRanks

Click here to get full coverage on MaxCyte Shareholders Reelect Directors and Ratify Auditor - TipRanks

MaxCyte Shareholders Reelect Directors and Ratify Auditor  TipRanks

MaxCyte Shareholders Reelect Directors and Ratify Auditor - TipRanks

Click here to get full coverage on MXCT Q1 2026 Earnings: EPS Beat Estimates by 50.98% Despite Negative Earnings - EPS Surprise History - newsline.com

MXCT Q1 2026 Earnings: EPS Beat Estimates by 50.98% Despite Negative Earnings - EPS Surprise History  newsline.com

MXCT Q1 2026 Earnings: EPS Beat Estimates by 50.98% Despite Negative Earnings - EPS Surprise History - newsline.com

Click here to get full coverage on MXCT Q1 2026 Earnings: EPS Beat Estimates by 50.98% Despite Negative Earnings - Profit Inflection Point - newsline.com

MXCT Q1 2026 Earnings: EPS Beat Estimates by 50.98% Despite Negative Earnings - Profit Inflection Point  newsline.com

MXCT Q1 2026 Earnings: EPS Beat Estimates by 50.98% Despite Negative Earnings - Profit Inflection Point - newsline.com

Click here to get full coverage on Is MaxCyte (MXCT) Stock Good for Passive Investors | Price at $0.74, Down 1.31% - Zero Lag EMA - newsline.com

Is MaxCyte (MXCT) Stock Good for Passive Investors | Price at $0.74, Down 1.31% - Zero Lag EMA  newsline.com

Is MaxCyte (MXCT) Stock Good for Passive Investors | Price at $0.74, Down 1.31% - Zero Lag EMA - newsline.com

Click here to get full coverage on MaxCyte (MXCT) Reports Strong Q1 2026 — Revenue $N/A, EPS Beats - Balance Sheet Strength - newsline.com

MaxCyte (MXCT) Reports Strong Q1 2026 — Revenue $N/A, EPS Beats - Balance Sheet Strength  newsline.com

MaxCyte (MXCT) Reports Strong Q1 2026 — Revenue $N/A, EPS Beats - Balance Sheet Strength - newsline.com

Click here to get full coverage on MXCT (MaxCyte Inc.) shares climb more than four percent after Q4 2025 EPS tops consensus analyst expectations. - Geographic Revenue Trends - newsline.com

MXCT (MaxCyte Inc.) shares climb more than four percent after Q4 2025 EPS tops consensus analyst expectations. - Geographic Revenue Trends  newsline.com

MXCT (MaxCyte Inc.) shares climb more than four percent after Q4 2025 EPS tops consensus analyst expectations. - Geographic Revenue Trends - newsline.com

Click here to get full coverage on MaxCyte, Inc. (MXCT) Stock Forecast & Price Prediction 2026–2030 - CoinCodex

MaxCyte, Inc. (MXCT) Stock Forecast & Price Prediction 2026–2030  CoinCodex

MXCT

Price Chart

Key Statistics

Technicals

About MXCT

Latest News

MaxCyte (NASDAQ: MXCT) investors reelect board and ratify auditor - Stock Titan

MaxCyte Disclosed Failure to Satisfy a Continued Listing Rule or Standard - TradingView

MaxCyte (MXCT) Launches ExPERT DTx Platform to Accelerate High-Throughput Drug Discovery - Yahoo Finance

Advanced Charts

Top Gainers

Top Losers